Skip to main content
OpenTrials
Completed

NCT Number: NCT01398748

Intranasal Glutathione in Parkinson's Disease

Excessive free radical formation and depletion of the brain's primary antioxidant, glutathione, are established components of Parkinson's disease (PD) pathophysiology. While there is rationale for the therapeutic use of reduced glutathione (GSH) in PD, and even some preliminary evidence to suggest the use of GSH can lead to symptomatic improvement, obstacles surrounding currently employed delivery methods have hindered the clinical utility of this therapy. Intranasal GSH, (in)GSH, is a novel method of delivery for this popular CAM therapy in patients with PD, and bypasses the obstacles associated with other delivery methods. It has been used in clinical practice since 2005. The aim of this study is to evaluate safety, tolerability, and preliminary absorption data of (in)GSH in volunteers with PD in a Phase I single ascending dose escalation study.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Parkinson's Disease (PD) Basal Ganglia Diseases Brain Diseases Central Nervous System Diseases Movement Disorders Nervous System Diseases Neurodegenerative Diseases Parkinson Disease Parkinsonian Disorders Synucleinopathies

Age range

21 year–100 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Bastyr Clinical Research Center

Kenmore, Washington, 98023, United States

About this study

Individuals will be randomized to one of three treatment (100 mg GSH/ ml, 200 mg GSH/ ml, or placebo) arms in a double-blind fashion. All study medication will be administered 1 ml three times daily for three months, with a one-month wash out.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diagnosis of Parkinson's Disease made by neurologist within previous 10 years
  • Modified Hoehn and Yahr Stage <3
  • Age >20
  • Subjects must be able to attend study visits at screening, baseline, weeks 4, 8, 12, 16
  • Subjects must be able to demonstrate self-administration of study medication or have active caregiver who can administer daily.
  • Dose and frequency of all pharmaceutical medications must be stable for one month prior to enrollment.
  • Diet, exercise and supplementation must be kept constant throughout participation in study
  • Ability to read and speak English

Exclusion criteria

  • Dementia as evidenced by Montreal Cognitive Assessment (MoCA) <24
  • Diseases with features common to Parkinson's Disease (eg. essential tremor, multiple system atrophy, progressive supranuclear palsy)
  • Epilepsy
  • History of stroke, CVA
  • Elevated levels of ALT, AST, BUN or creatinine
  • Chronic sinusitis as defined by SNOT-20 score >1.0 on items 1-10.
  • Presence of other serious illness
  • History of brain surgery
  • History of structural brain damage
  • History of intranasal telangiectasia
  • Supplementation with glutathione and agents shown to increase glutathione will not be permitted and will require a 90 day washout period.
  • Pregnant or at risk of becoming pregnant.

Treatment and study plan

Intranasal glutathione - (in)GSH

Drug

Intranasal glutathione-Tripeptide glutathione 100 mg/ml. 1 ml 3x per day TID X 12 weeks at 2100mg in 15 participants

Saline Intranasal Delivery

Drug

Saline administration 1ml 3x/day 12 weeks in 15 participants

Primary outcomes

  1. Determination of Safety

    Time frame: 12 weeks

    1a. Laboratory monitoring for adverse events will include CBC, ALT, AST, BUN, creatinine, uric acid, and urinalysis. Data will be collected throughout the 12-week intervention and at 1-mo following cessation of the study medication.

    1b. Clinical adverse events will be measured using a daily patient diary and record score cards specifically screening for sinus irritation. Monitoring of Side Effects System (MOSES) will be used to screen for systemic and generalized adverse events.

    1c. Effect on PD symptoms will be measured by the UPDRS to screen for accelerated disease activity.

  2. Determination of Tolerability

    Time frame: 12 weeks

    Participants will be asked to keep a daily log and unused study medication will be measured at each clinical visit. Tolerability will be measured by frequency and severity of reported adverse events and withdrawal from study. The goal will be to identify the maximum tolerated dose (MTD) which will be defined as the highest dose achieving adherence, as defined as 80% of the group taking the prescribed dose 80% of the time.

Secondary outcomes

  1. Description of systemic absorption characteristics

    Time frame: 12 weeks

    Red blood cell GSH levels will be measured at baseline, 4 weeks, and 12 weeks.

Sponsors and collaborators

Lead sponsor

Bastyr University

Other

Collaborators

  • National Center for Complementary and Integrative Health (NCCIH)

Registry information

Official study title

A Phase 1 Study of Intranasal Reduced Glutathione in Parkinson's Disease

Important dates

Study start
2012
Primary completion
2016
Study completion
2016
First posted
Jul 21, 2011
Registry last updated
Jul 31, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.